Ligand Pharmaceuticals: Reliable Midcap Pharma With Perfected High Growth Business Model [Seeking Alpha]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Seeking Alpha
LGND's transition in 2022 to a capital and technology provider for drug and device developers has fueled robust share and earnings growth. Bank of America initiated coverage with a Buy rating and a $244 price target, citing LGND's unique model and experienced investment team. Further upside is anticipated if LGND continues to meet annual and long-term growth targets, increasing investor confidence and engagement. NVS/iStock via Getty Images This is my tenth Ligand ( LGND ) article, following my most recent 06/2025's "Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward." In Powers Forward , I rated Ligand as a "Buy". It has since scored an impressive ~58% gain. In this This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of LGND, GILD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says [Yahoo! Finance]Yahoo! Finance
- Ligand Pharmaceuticals (LGND) is now covered by Bank of America Corporation. They set a "buy" rating and a $244.00 price target on the stock.MarketBeat
- How The Ligand Pharmaceuticals (LGND) Story Is Shifting Around QTORIN And Royalty Growth [Yahoo! Finance]Yahoo! Finance
- Ligand to Participate in March Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Ligand to Participate in March Investor ConferencesGlobeNewswire
LGND
Earnings
- 2/26/26 - Beat
LGND
Sec Filings
- 3/13/26 - Form 4
- 3/11/26 - Form 144
- 3/6/26 - Form 4
- LGND's page on the SEC website